BFRI BIOFRONTERA INC

Biofrontera Inc. to Present at the LD Micro Main Event XV Investor Conference

Biofrontera Inc. to Present at the LD Micro Main Event XV Investor Conference

WOBURN, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that Erica Monaco, Chief Executive Officer, will be presenting and meeting with registered investors at the LD Micro Main Event XV that will be held October 25-27, 2022 at the Luxe Sunset Boulevard Hotel in Southern California.

Event:LD Micro Main Event XV
Date:Wednesday, October 26, 2022
Presentation Time:4:00 PM Pacific Time (7:00 PM Eastern Time)
Location:Luxe Sunset Boulevard Hotel, Los Angeles, CA
Webcast:

A webcast of the presentation will be live and archived on the section of the company website. Institutional investors registered for the conference who would like to meet with Erica Monaco and Hermann Lübbert, Executive Chairman of Biofrontera Inc., please contact LD Micro directly or the BFRI investor relations team.

About Biofrontera Inc.

Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company’s licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit .

Contacts

Biofrontera Inc.

Anke zur Mühlen



LHA Investor Relations

Tirth T. Patel



# # #



EN
20/10/2022

Underlying

BFRIBIOFRONTERA INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BIOFRONTERA INC

 PRESS RELEASE
Free
BFRI BIOFRONTERA INC

Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of...

Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book Biofrontera received patent approval for the revised formulation of Ameluz® in April 2025, extending patent protection through to December 2043.The Orange Book is published by the U.S. Food and Drug Administration (FDA) and lists all approved prescription drug products, along with patent and exclusivity information.Inclusion signifies FDA recognition of the revised formulation's approved status and its intellectual property protection. WOBU...

June 3, 2025 1 EN
 PRESS RELEASE
Free
BFRI BIOFRONTERA INC

Biofrontera Inc. Reports First Quarter 2025 Financial Results and Prov...

Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update Conference call begins at 10:00 a.m. Eastern time on Friday, May 16, 2025 WOBURN, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results for the three months ended March 31, 2025 and provided a business update. Highlights from the first quarter of 2025 and subsequent weeks included the following: Total revenues for the first quarter of 202...

May 15, 2025 1 EN
 PRESS RELEASE
Free
BFRI BIOFRONTERA INC

Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043...

Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris Biofrontera has received patent approval for the revised formulation of Ameluz®, which extends patent protection through to December 2043Ameluz PDT offers the potential for effective treatment of moderate to severe acne without the side effects associated with some systemic therapies4Approximately 50 million people in the US are suffering from acne vulgaris...

May 15, 2025 1 EN
 PRESS RELEASE
Free
BFRI BIOFRONTERA INC

Biofrontera and Almirall Launch the Hats On Challenge to Raise Awarene...

Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis The initiative is a social media challenge ahead of Global AK Awareness Day, on May 24, which supports the work of The Skin Cancer Foundation and EuromelanomaThe Hats On Challenge provides an opportunity to take part in raising awareness of AK.Actinic Keratosis (AK) is a rough, scaly patch on the skin caused by years of sun exposure. If left untreated, AK can develop into squamous cell carcinoma, a type of skin cancer. Woburn, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc....

May 1, 2025 1 EN
 PRESS RELEASE
Free
BFRI BIOFRONTERA INC

Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and...

Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update Conference scheduled for Friday, March 21, 2025 at 10:00 a.m. Eastern time Woburn, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today reported financial results for the three and twelve months ended December 31, 2024. Highlights from 2024 and subsequent weeks include: Reported record total revenues of $37.3 million for 2024, reflecting a 9.5% increase f...

March 21, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch